Pricing
  1. US-listed companies
  2. CymaBay Therapeutics, Inc.
  3. Financials
  4. Cash and cash equivalents

CymaBay Therapeutics, Inc. (CBAY)

Market cap
$3.7B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 2023207+917.87%
Dec 31, 202220-83.87%
Dec 31, 2021126+346.23%
Dec 31, 202028+13.37%
Dec 31, 201925-49.24%
Dec 31, 201849+112.52%
Dec 31, 201723+119.67%
Dec 31, 201610+36.19%
Dec 31, 20158-33.49%
Dec 31, 201412-52.52%
Dec 31, 201324

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat